--cash on hand =2.2c
--licensing deal with SIOC (Avexa's HIV integrase inhibitor program)=30c (no development cost)
-initiate an independent review may make apricitabine(ATC) alive =70c
-all other asset =10c(conservertive estimate)
2.2+30+70+10=1.122per share
the share price now only 3 cent now..... great buy
Add to My Watchlist
What is My Watchlist?